452
IRUS TotalDownloads
Altmetric
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society Consensus Panel
File | Description | Size | Format | |
---|---|---|---|---|
ehx144.pdf | Published version | 1.23 MB | Adobe PDF | View/Open |
Title: | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society Consensus Panel |
Authors: | Ference, BA Ginsberg, HN Graham, I Ray, KK Packard, CJ Bruckert, E Hegele, RA Krauss, RM Raal, FJ Schunkert, H Watts, GF Boren, J Fazio, S Horton, JD Masana, L Nicholls, SJ Nordestgaard, BG Van de Sluis, B Taskinen, M Tokgozoglu, L Landmesser, U Laufs, U Wiklund, O Stock, JK Chapman, MJ Catapano, AL |
Item Type: | Journal Article |
Abstract: | Aim: To appraise the clinical and genetic evidence that low-density lipoproteins (LDL) cause atherosclerotic cardiovascular disease (ASCVD). Methods and Results: We assessed whether the association between LDL and ASCVD fulfills the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150,000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD. |
Issue Date: | 24-Apr-2017 |
Date of Acceptance: | 1-Mar-2017 |
URI: | http://hdl.handle.net/10044/1/45373 |
DOI: | https://dx.doi.org/10.1093/eurheartj/ehx144 |
ISSN: | 1522-9645 |
Publisher: | Oxford University Press (OUP) |
Start Page: | 2459 |
End Page: | 2472 |
Journal / Book Title: | European Heart Journal |
Volume: | 38 |
Issue: | 32 |
Copyright Statement: | © The Author 2017. Published on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
Keywords: | Science & Technology Life Sciences & Biomedicine Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Atherosclerosis Cardiovascular disease Low-density lipoprotein Mendelian randomization Clinical trials Statin Ezetimibe PCSK9 Causality Recommendations CORONARY-HEART-DISEASE HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA CHOLESTEROL-FED RABBITS STATIN THERAPY MENDELIAN RANDOMIZATION LDL CHOLESTEROL GENERAL-POPULATION RISK METAANALYSIS TRIAL 1102 Cardiovascular Medicine And Haematology Cardiovascular System & Hematology |
Publication Status: | Published |
Appears in Collections: | School of Public Health |